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INTRODUCTION
Epidermal hyperplasia -excessive keratinocyte proliferation, leading to expansion of the epidermis in association with epidermal shedding -is the major manifestation of psoriasis (Kreuger et al., 1984; Fry, 1988) . Epidermal hyperplasia also occurs under physiological conditions (i.e., during wound-healing) (Stenn and Malhotra, 1992) and is a consequence in many individuals of topical treatment with all-trans retinoic acid (RA) or its precursor, all-trans retinol (Kang et al., 1995) . Previous studies have demonstrated that epidermal hyperplasia and normal epidermal growth are, to some degree, at least, differentially regulated (Tavakkol et al., 1999) . It is not unreasonable, therefore, that pharmacological agents might be identified that interfere with hyperplastic epidermal growth without disturbing normal skin physiology.
Previously, we identified a novel anti-proliferative and pro-apoptotic 1,4-benzodiazepine, termed Bz-423 (Blatt et al., 2002; Boitano et al., 2003a) . Bz-423 and congeners with similar activity differ from benzodiazepines currently in clinical use by the presence of a hydrophobic substituent at the C-3 position, which blocks binding to the central benzodiazepine receptor and renders binding to the peripheral benzodiazepine receptor weak (Boitano et al., 2003b) . The anti-proliferative and cytotoxic properties of Bz-423 are evident against malignant B and T cell lines in vitro. In vivo, this compound reduces pathologically-expanded populations of B and T lymphocytes in autoimmune-prone (NZB x NZW) F1 and MRL-lpr strains of mice, respectively (Blatt et al., 2002; Bednarski et al., 2003) . Reduction of activated lymphocytes by results in less autoimmune-mediated kidney damage (glomerulonephritis), preserves renal function, and in MRL-lpr mice, reduces autoimmune arthritis specific to this strain. Experiments with normal immune mice show no evidence of toxicity against normal lymphocyte populations, bone marrow cells or solid tissues including liver, heart, gastrointestinal mucosa and skin. The potent antiproliferative actions of Bz-423, its effectiveness at limiting disease manifestations in lupus, and its low index of toxicity in animals led us to consider if this agent might be used to treat hyperplastic skin diseases such as psoriasis. As a first step, we used a model of retinoid-induced epidermal hyperplasia in human skin organ culture as the test system. Past studies have demonstrated that while the etiologies are different, retinoid hyperplasia (Varani et al., 2001) , like the hyperplasia in psoriasis (Gottlieb et al., 1988; Elder et al., 1989; Cook et al., 1992; Peipkorn et al., 1998; Varani et al., 1998; Peipkorn et al., 2003) , involves intra-epidermal production of ligands for the epidermal growth factor (EGF) receptor, and autocrine or paracrine EGF receptor activation. The results, presented here, demonstrate significant reduction in retinoid-stimulated hyperplasia without detrimental effects on normal keratinocyte proliferation or fibroblast function.
This article has not been copyedited and formatted. The final version may differ from this version. that differs from Bz-423 only by substitution of the phenolic hydroxyl group with a methoxy group, were synthesized as described previously (Bednarski et al., 2003) . Three molecules used in this study for comparative purposes, including clonazepam and 4-chlorodiazepam (benzodiazepines that tightly bind the central and peripheral [mitochondrial] benzodiazepine receptors, respectively) and PK11195 an isoquinoline that binds tightly to the peripheral benzodiazepine receptor, were obtained from Sigma-Aldrich (St. Louis, MO). Each of the compounds was dissolved in dimethyl sulfoxide (DMSO) at 20 mg/ml and diluted in culture medium at the time of use. The concentration of DMSO in the final mixture was always less than 0.05 µl per ml -well below concentrations at which biological effects are observed in monolayer cultures of human skin cells or organ cultures of human skin under the conditions employed here (Varani et al. 1994) .
RA was obtained from Sigma-Aldrich (St. Louis, MO). The retinoid was diluted in DMSO at 20 mg/ml and stored frozen. At the time of use, the RA stock solution was diluted in culture medium and used in organ culture studies at a final concentration of 1.0 µg/ml. DMSO was present at a final concentration of 0.5% (v/v) Other than to maintain the tissue in a minimal volume of medium, nothing further was done to ensure a strict air-liquid interface. Incubation was for 8 days, with change of medium and fresh treatments every second day. At the end of the incubation period, tissue was fixed in 10% buffered formalin and examined histologically after staining with hematoxylin and eosin.
Routinely, 3-6 tissue sections were prepared from each block. Epidermal thickness measurements were made at 4 sites in each tissue section (distance from the dermal-epidermal juncture to the top of the viable portion of the epithelium) and averaged. Average thickness values for each group of tissues were determined. The organ culture procedure has been described in the past (Varani et al., 1993; Varani et al., 1994) .
Human epidermal keratinocytes and dermal fibroblasts in monolayer culture. Epidermal keratinocytes were isolated as described previously (Varani et al., 1994 Figure 2 and Table 2 . DMSO served as a negative control.
Proliferation was measured on day 3 by releasing the cells with trypsin/EDTA and enumerating them using a particle counter (Coulter Electronics, Hialeah, FL). Western blotting for total and phosphorylated forms of the EGF receptor and for total and phosphorylated forms of Erk 1/2 was carried out as described previously (Zeigler et al., 1999; Bhagavathula et al., 2004) . Briefly, samples were separated in SDS-PAGE under denaturing and Technologies, Inc., Beverly, MA). A Kodak -1000 X-OMAT processor was used to capture the positive images of the Western blots and these positive images were scanned and digitized. The digitized images were quantitated using NIH image analysis software.
Detection of intracellular reactive oxygen species (ROS).
2',7'-dichlorodihydrofluorescin diacetate (DCFH-DA, Molecular Probes, Eugene, OR) was prepared as a 10 mM stock solution in DMSO prior to each use. Cells growing in 48-well plates were loaded (30 minutes, 37 °C) with DCFH-DA (100 µM) added directly to culture media. The cells were then washed and placed in fresh media prior to treatment. After the indicated treatments, the fluorescence of the oxidized product 2',7'-dichlorofluorescin (DCF) was monitored by flow cytometry using a FACSCalibur (BD Bioscience, San Diego, CA). For each sample, 10,000 events were recorded and the data analyzed to determine median fluorescence intensity.
Statistical analysis.
Differences between groups in experiments with multiple groups were analyzed for statistical significance by ANOVA followed by paired-group comparisons. Where there were only two groups, the Student t-test was used. Data were analyzed as paired or unpaired as appropriate.
This article has not been copyedited and formatted. The final version may differ from this version. To confirm the concentration-dependent differences in growth inhibition versus cell death as detected in the proliferation assay, the capacity of Bz-423 to lethally injure keratinocytes was formally examined in a 4-hour cytotoxicity assay. Consistent with results from the proliferation assays, Bz-423 at 1 and 2 µM did not inhibit the ability of treated cells to replate successfully after exposure (i.e., was not cytotoxic) while at 4 µM, ability of the treated cells to replate was greatly reduced (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. In order to determine if the effects of Bz-423 on keratinocyte and fibroblast proliferation were specific for Bz-423, we compared the response to Bz-423 with responses to other selected benzodiazepines, and PK11195, which binds tightly to the peripheral benzodiazepine receptor.
One of the compounds examined was Bz-OMe, a congener of Bz-423 that differs from Bz-423
only by methylation of the phenolic hydroxyl group (see Figure 1 above). Bz-OMe has potent anti-proliferative and minimal cytotoxic activities against lymphoid cells (Boitano et al., 2003a) .
As expected, Bz-423 proved to be a more potent inhibitor of keratinocyte proliferation than the other compounds tested (Table 2 ). Bz-OMe was intermediary and the other benzodiazapines were inactive against keratinocytes and fibroblasts at concentrations up to 10 µM.
Bz-423 increases ROS in keratinocytes and fibroblasts.
In lymphoid cells, Bz-423 increases intracellular superoxide within 1 hour of treatment and this oxidant response is necessary for the cytotoxic and anti-proliferative effects that follow (Blatt et al., 2002; Boitano et al., 2003a) . To determine if the anti-proliferative and cytotoxic effects of Bz-423 in keratinocytes and fibroblasts similarly involve ROS generation, intracellular ROS levels in control and Bz-423-treated cells were measured. As shown in Figure 3 , a significant ROS response, assessed as median cell fluorescence from the ROS-sensitive indicator DCF, was observed in both cell types treated with Bz-423. ROS was detected at a dose of Bz-423 as low as 0.5 µM and the response increased in a dose-dependent fashion in both cell types. At all concentrations of Bz-423 tested, keratinocytes generated a greater ROS response than fibroblasts. As a second way to assess ROS generation, the percentage of cells with fluorescence values above baseline levels was determined. Similar differences between keratinocytes and fibroblasts were observed when ROS generation was evaluated in this manner (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. failed to show any additional histologic changes that could be ascribed to Bz-423. In particular, no differences in the cellularity or structure of the dermis, no changes in the dermal-epidermal interface, and no effects on keratinocyte differentiation and keratinization were evident. In addition, Bz-423 -treated specimens were notable for the lack of increased apoptotic cells. In additional studies (not shown), RA-exposed skin was treated with Bz-423 at different This article has not been copyedited and formatted. The final version may differ from this version. concentrations and examined for epidermal thickness. At 0.5 µM, epidermal thickening was also reduced but this concentration was less effective than 1 µM. A reduction in epidermal thickness was also observed at higher concentrations of Bz-423 (i.e., at 5 µM), but necrosis was also observed.
In addition to using epidermal thickness as a measure, we also assessed the effects of Bz- Finally, 2-mm skin biopsies from four donors were incubated in the absence of RA but treated with 1 µM Bz-423. In the normal skin, minimal change in histological structure was observed. Likewise, there was minimal change in epidermal thickness (Figure 8 ).
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DISCUSSION
Bz-423 was initially discovered as a pro-apoptotic agent that has the capacity to effectively treat auto-immune disease in several animal models (Blatt et al., 2002; Bednarski et al., 2003) . Other work has demonstrated the compound's ability to block proliferation independently of cytotoxicity in cells derived from malignant B cell neoplasms (Boitano et al., 2003a ). The present study demonstrates that Bz-423 has the capacity to inhibit (retinoidinduced) hyperplastic growth in the epidermis of human skin without affecting normal skin physiology.
Capacity to interfere with retinoid-induced epidermal hyperplasia without affecting normal epidermal growth or dermal function provides a significant therapeutic opportunity. It is generally accepted that hyperplasia in skin following topical application of RA accounts for the attendant skin irritation that accompanies retinoid treatment in many individuals (Kang et al., 1995) . The cellular and molecular events that underlie the irritation response are not fully understood. Elaboration of interleukin-1 (IL-1) and other cytokines within the rapidly proliferating keratinocyte microenvironment is thought to be involved (Wood et al., 1996; MaasSzabowski, et al., 2000) . These cytokines produce localized changes in vascular function (Nguyen et al., 2001) , which, in turn, promote edema and inflammatory cell influx into the skin.
Concomitantly, shedding of excess epithelium produces the "skin flaking" commonly observed in retinoid-treated skin. At one time, it was believed that retinoid action in the epidermis and dermis occurred through the same pathways. As such, the beneficial effects of retinoid treatment in the dermis (i.e., fibroblast activation, increased procollagen production and decreased elaboration of matrix metalloproteinases) (Griffiths et al., 1993; Fisher et al., 1996; This article has not been copyedited and formatted. The final version may differ from this version. (Varani et al. 2003 ).
An agent with the capacity to interfere with epidermal hyperplasia may also find use as an anti-psoriatic agent. A number of approaches have led to the conclusion that the triggering event in psoriasis is an immune system defect (Valdimarsson et al., 1995; Austin et al., 1999) .
Nevertheless, the down-stream events that precipitate psoriatic hyperplasia (like those in retinoid hyperplasia), involve keratinocyte growth regulation (Gottlieb et al., 1988; Elder et al., 1989; Cook et al., 1992; Peipkorn et al., 1998; Varani et al., 1998; Peipkorn et al., 2003) . Utility of agents that target abnormal keratinocyte proliferation for treatment of hyperplastic skin diseases will, ultimately, require formulation for topical delivery. Although it is not yet known whether
Bz-423 and congeners can be successfully formulated for topical delivery, the physical properties of Bz-423 and related compounds (e.g., formula weight <500 molecular weight units) provide a highly favorable context from which to pursue this goal.
The mechanism by which Bz-423 suppresses hyperplastic epidermal growth is not fully understood. Past studies conducted with malignant B-lymphocytes demonstrated that low-level generation of intracellular ROS was correlated with growth inhibition and generation of higher amounts of ROS with cytotoxicity (Boitano et al., 2003a) . Similarly, it was shown in the present study that concentrations of Bz-423 that induced ROS production in epidermal keratinocytes also reduced keratinocyte proliferation in monolayer culture and suppressed hyperplasia in organ culture. Furthermore, epidermal keratinocytes, which were more sensitive to the growthinhibiting effects of Bz-423 than dermal fibroblasts, generated greater amounts of ROS at lower concentrations of Bz-423 than did fibroblasts. Arguing against this, however, is the fact that Past studies have shown that epidermal hyperplasia (including both retinoid hyperplasia and psoriasis) involves intra-cutaneous production of ligands for the EGF receptor, leading to autocrine or paracrine EGF receptor activation (Gottlieb et al., 1988; Elder et al., 1989; Cook et al., 1992; Pittelkow et al. 1993; Peipkorn et al., 1998; Varani et al., 1998; Varani et al. 2001; Peipkorn et al., 2003) , and down-stream signaling through mitogen activated protein (MAP) kinase pathways (Alpin et al., 1998) . In the present study, we did not observe a change in phosphorylation status of the EGF receptor as a consequence of treatment with Bz-423. On the other hand, Erk 1/2 phosphorylation was reduced by the same treatment. Erk 1/2 activation (evidenced by phosphorylation) is a down-stream target of EGF receptor activation, but also occurs in response to multiple other receptor-ligand interactions (Alpin et al., 1998) . It is reasonable to suggest that Bz-423 uncouples signaling events linking EGF receptor activation to Erk 1/2 but might also act to interfere with signals originating from other sources that also induce Erk 1/2 activation. Of interest in this regard, past studies have shown that thiazoladinediones also inhibit ERK 1/2 phosphorylation in keratinocytes following EGF stimulation (Bhagavathula et al. 2004 ). Similar to BZ-423, the thiazoladinediones also suppress epidermal hyperplasia in organ culture. More importantly, these agents also reduce epidermal thickness of psoriatic lesional skin transplanted to SCID mice (Ellis et al. 2000) and have proven clinically useful in treatment of psoriasis (Ellis et al. 2000; Malhotra et al. 2002) . Perhaps Bz-423 will also prove to be beneficial in psoriasis. It should be noted that it is not necessary to completely suppress Erk1/2 activation to prevent epidermal hyperplasia. In fact, complete suppression of Erk phosphorylation is associated with cytotoxicity rather than cytostasis (Zeigler et al., 1999) . Cl JPET #75929 Figure 1 
